ACTRN12617000473369进行中（未招募）1 期
Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age > 18 years
- •Prior allogeneic stem cell transplant for a haematological malignancy
- •Confirmed relapse or persistent haematological malignancy post allogeneic transplant
- •Immunosuppression cessation for minimum 2 weeks
排除标准
- •Current evidence of any grade of GVHD
- •Prior history of grade 2 or higher acute GVHD
- •Moderate chronic GVHD within the previous 6 months or any prior history of severe chronic GVHD
- •Known autoimmune disease
- •Positive hepatitis B virus surface antigen
- •Positive hepatitis C virus antibody
- •Known HIV infection
研究者
相似试验
已完成
2 期
A clinical trial of nivolumab in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (NCCH1510,OSCAR trial)clear cell sarcoma and alveolar soft part sarcomaJPRN-UMIN000023665ational Cancer Center20
进行中（未招募）
1 期
ivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade gliomaewly diagnosed High-Grade Gliomas (HGG)MedDRA version: 20.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002688-24-FRGustave Roussy40
招募中
Unknown
A prospective observational study of nivolumab plus chemotherapy for advanced gastric cancer using CyberOncology (WJOG15922G)JPRN-UMIN000049928West Japan Oncology Group100
进行中（未招募）
1 期
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003334-25-DEniversity of Cologne90
进行中（未招募）
1 期
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapyMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002986-36-ITFONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI184